U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H12F2N6O
Molecular Weight 306.2713
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUCONAZOLE

SMILES

c1cc(c(cc1F)F)C(Cn2cncn2)(Cn3cncn3)O

InChI

InChIKey=RFHAOTPXVQNOHP-UHFFFAOYSA-N
InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

HIDE SMILES / InChI

Molecular Formula C13H12F2N6O
Molecular Weight 306.2713
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf

Fluconazole, a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which thereby prevents the formation of ergosterol which is an essential component in the fungal cell membrane. Indicated for the treatment of fungal infections.

CNS Activity

Curator's Comment:: Fluconazole readily penetrated the blood-CSF/blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.127000000000000002 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Diflucan

Approved Use

DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, DIFLUCAN was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis.

Launch Date

633484800000
Curative
Diflucan

Approved Use

DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, DIFLUCAN was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis.

Launch Date

633484800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.54 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.61 μg/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
6.72 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
11.4 μg/mL
4 mg/kg 1 times / day multiple, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
14.1 μg/mL
8 mg/kg 1 times / day multiple, intravenous
dose: 8 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
2.9 μg/mL
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
5.5 μg/mL
2 mg/kg 1 times / day multiple, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
9.8 μg/mL
8 mg/kg single, oral
dose: 8 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.4 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
156.1 ug*h/mL
150 mg single, oral
dose: 150 mg
route of administration: oral
experiment type: single
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: unhealthy
age:
sex: F
food status:
79.5 ug*h/g
150 mg single, oral
dose: 150 mg
route of administration: oral
experiment type: single
co-administered:
FLUCONAZOLE vaginal fluid
Homo sapiens
population: unhealthy
age:
sex: F
food status:
85.3 ug*h/mL
150 mg single, oral
dose: 150 mg
route of administration: oral
experiment type: single
co-administered:
FLUCONAZOLE vaginal fluid
Homo sapiens
population: unhealthy
age:
sex: F
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
46.2 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
30 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
15.2 h
4 mg/kg 1 times / day multiple, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
17.6 h
8 mg/kg 1 times / day multiple, intravenous
dose: 8 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
25 h
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
17.4 h
2 mg/kg 1 times / day multiple, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
19.5 h
8 mg/kg single, oral
dose: 8 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
88.5%
FLUCONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg/kg 1 times / day steady, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 17 years
Health Status: unhealthy
Age Group: 0 - 17 years
Sex: M+F
Sources:
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (5.4%)
Abdominal pain (2.8%)
Nausea (2.3%)
Diarrhea (2.1%)
Sources:
5.3 mg/kg 1 times / day steady, oral
Recommended
Dose: 5.3 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 5.3 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: unknown
Sources:
Other AEs: Anaemia, Transaminases increased...
Other AEs:
Anaemia (1 patient)
Transaminases increased (1 patient)
Sources:
6 mg/kg 1 times / day steady, oral
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: M+F
Sources:
Disc. AE: Nephrotoxicity, Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Nephrotoxicity
Hepatotoxicity
Myelosuppression
Sources:
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 16 - 73 years
Health Status: unhealthy
Age Group: 16 - 73 years
Sex: M+F
Sources:
Disc. AE: Anemia, Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Anemia (3 patients)
Transaminases increased (1 patient)
Sources:
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Other AEs: Xerosis, Alopecia...
Other AEs:
Xerosis (8 patients)
Alopecia (11 patient)
Fatigue (13 patients)
Nausea and vomiting (10 patients)
Anorexia (7 patients)
Headache (6 patients)
Arthralgia (5 patients)
Cheilitis (4 patients)
Xerostomia (2 patients)
Dizziness (3 patients)
Neuropathy (2 patients)
Abdominal discomfort (2 patients)
ALP increased (2 patients)
Sources:
150 mg 1 times / day steady, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Abortions spontaneous...
Other AEs:
Abortions spontaneous (249 patients)
Sources:
150 mg 1 times / day steady, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Abortions spontaneous...
Other AEs:
Abortions spontaneous (345 patients)
Sources:
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (13%)
Nausea (7%)
Abdominal pain (6%)
Diarrhea (3%)
Dyspepsia (1%)
Dizziness (1%)
Taste perversion (1%)
Sources:
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Glucose high, Acute depression...
Other AEs:
Glucose high (serious, 1 patient)
Acute depression (serious, 1 patient)
Agitation (below serious, 1 patient)
Aspartate aminotransferase increased (below serious, 1 patient)
Blood alkaline phosphatase high (below serious, 1 patient)
Taste altered (below serious, 1 patient)
Bilirubin total high (below serious, 3 patients)
Chlamydial infection (below serious, 1 patient)
Constipation (below serious, 1 patient)
Subcutaneous cyst (below serious, 1 patient)
Depressed mood (below serious, 2 patients)
Dry mouth (below serious, 2 patients)
Flank pain (below serious, 1 patient)
Blood glucose increased (below serious, 3 patients)
Headache NOS (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Generalized joint pain (below serious, 1 patient)
Lightheadedness (below serious, 1 patient)
Lymphadenopathy cervical (below serious, 1 patient)
Nausea (below serious, 4 patients)
Nose bleed (below serious, 1 patient)
Prostatitis (below serious, 1 patient)
Sexual dysfunction (below serious, 1 patient)
Syphilis (below serious, 1 patient)
Tooth infection (below serious, 1 patient)
Upper respiratory infection (below serious, 1 patient)
Visual disturbance (below serious, 1 patient)
Vomiting (below serious, 1 patient)
Weight loss (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 2.1%
15 mg/kg 1 times / day steady, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 17 years
Health Status: unhealthy
Age Group: 0 - 17 years
Sex: M+F
Sources:
Nausea 2.3%
15 mg/kg 1 times / day steady, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 17 years
Health Status: unhealthy
Age Group: 0 - 17 years
Sex: M+F
Sources:
Abdominal pain 2.8%
15 mg/kg 1 times / day steady, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 17 years
Health Status: unhealthy
Age Group: 0 - 17 years
Sex: M+F
Sources:
Vomiting 5.4%
15 mg/kg 1 times / day steady, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, 0 - 17 years
Health Status: unhealthy
Age Group: 0 - 17 years
Sex: M+F
Sources:
Anaemia 1 patient
5.3 mg/kg 1 times / day steady, oral
Recommended
Dose: 5.3 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 5.3 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: unknown
Sources:
Transaminases increased 1 patient
5.3 mg/kg 1 times / day steady, oral
Recommended
Dose: 5.3 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 5.3 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: unknown
Sources:
Hepatotoxicity Disc. AE
6 mg/kg 1 times / day steady, oral
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: M+F
Sources:
Myelosuppression Disc. AE
6 mg/kg 1 times / day steady, oral
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: M+F
Sources:
Nephrotoxicity Disc. AE
6 mg/kg 1 times / day steady, oral
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 1 - 12 month
Health Status: unhealthy
Age Group: 1 - 12 month
Sex: M+F
Sources:
Transaminases increased 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 16 - 73 years
Health Status: unhealthy
Age Group: 16 - 73 years
Sex: M+F
Sources:
Anemia 3 patients
Disc. AE
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 16 - 73 years
Health Status: unhealthy
Age Group: 16 - 73 years
Sex: M+F
Sources:
Nausea and vomiting 10 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Alopecia 11 patient
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Fatigue 13 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
ALP increased 2 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Abdominal discomfort 2 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Neuropathy 2 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Xerostomia 2 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Dizziness 3 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Cheilitis 4 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Arthralgia 5 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Headache 6 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Anorexia 7 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Xerosis 8 patients
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 46.1 years
Health Status: unhealthy
Age Group: 46.1 years
Sex: M+F
Sources:
Abortions spontaneous 249 patients
150 mg 1 times / day steady, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Abortions spontaneous 345 patients
150 mg 1 times / day steady, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Dizziness 1%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Dyspepsia 1%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Taste perversion 1%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Headache 13%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Diarrhea 3%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Abdominal pain 6%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Nausea 7%
150 mg single, oral
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Agitation below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aspartate aminotransferase increased below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood alkaline phosphatase high below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chlamydial infection below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Flank pain below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Generalized joint pain below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache NOS below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lightheadedness below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lymphadenopathy cervical below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nose bleed below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostatitis below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sexual dysfunction below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Subcutaneous cyst below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Syphilis below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Taste altered below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tooth infection below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Upper respiratory infection below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Visual disturbance below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Weight loss below serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Depressed mood below serious, 2 patients
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 2 patients
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bilirubin total high below serious, 3 patients
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood glucose increased below serious, 3 patients
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 4 patients
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acute depression serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Glucose high serious, 1 patient
100 mg 2 times / day steady, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: steady
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [IC50 13.1 uM]
yes (co-administration study)
Comment: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf#page=14 for DDIs
moderate [IC50 30.3 uM]
yes (co-administration study)
Comment: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf#page=14 for DDIs
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
strong [IC50 12.3 uM]
yes (co-administration study)
Comment: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf#page=14 for DDIs
weak [Ki 529 uM]
weak
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
1999 Dec
Potential fluconazole-induced carbamazepine toxicity.
1999 Jul-Aug
1H and 13C nuclear magnetic resonance studies of the sites of protonation in itraconazole and fluconazole.
1999 Jun
Antimicrobial activity of polycationic peptides.
1999 Nov
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
2000 Apr
Optically active antifungal azoles. X. Synthesis and antifungal activity of N.
2000 Dec
Syncope associated with concurrent amitriptyline and fluconazole therapy.
2000 Dec
Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
2000 Dec
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.
2000 Jun
Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.
2000 Mar
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
2000 Mar
In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
2000 May
Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg/mL.
2000 Oct
Anti-Candida activity of a new platinum derivative.
2000 Oct
Penicillium marneffei: types and drug susceptibility.
2001
In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs.
2001
Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital.
2001
Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients.
2001 Apr
Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy.
2001 Apr
Candida dubliniensis at a cancer center.
2001 Apr 1
Antifungal and immunomodulating activities of 1,4-benzothiazine azole derivatives: review.
2001 Feb
Effect of ketoconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by Candida albicans.
2001 Feb
Determination of minumum inhibitory concentrations of Candida species isolated from vaginal swab specimens by using broth macrodilution and E-test.
2001 Feb
Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit.
2001 Feb
Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant.
2001 Feb
Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
2001 Feb 1
Treating onychomycosis.
2001 Feb 15
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
2001 Jan
Clinico-myocological profile of tinea capitis in North India and response to griseofulvin.
2001 Jan
Coccidioidomycosis in adolescents with lupus nephritis.
2001 Jan
Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
2001 Jan
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
2001 Jan
The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
2001 Jan 15
Candidiasis in a cured MB patient.
2001 Jan-Mar
Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients.
2001 Mar
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
2001 Mar
Fluconazole-impregnated beads in the management of fungal infection of prosthetic joints.
2001 Mar
Treatment for coccidioidomycosis in pregnancy?
2001 Mar
Fluconazole dose recommendation in urinary tract infection.
2001 Mar
The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus.
2001 Mar
Candidal endophthalmitis after keratoplasty.
2001 Mar
Candidal endophthalmitis in a renal transplant patient.
2001 Mar
Access to fluconazole in less-developed countries.
2001 Mar 31
Susceptibility of fungal or yeast bloodstream isolates to antifungals: results from a national study.
2001 Mar-Apr
Therapy for fungal infections in leukemia.
2001 May
Patents

Sample Use Guides

Dosage and Administration in Adults:
Route of Administration: Oral
Fluconazole inhibited Candida albicans with MIC 0.125-16 ug/ml
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:04:58 UTC 2021
Edited
by admin
on Fri Jun 25 21:04:58 UTC 2021
Record UNII
8VZV102JFY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUCONAZOLE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
1H-1,2,4-TRIAZOLE-1-ETHANOL, 1-(2,4-DIFLUOROPHENYL)-1-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-
Common Name English
DIFLUCAN
Brand Name English
FLUCONAZOLI [WHO-IP LATIN]
Common Name English
BAYT006267
Code English
BAYT-006267
Code English
FLUCONAZOLE [MI]
Common Name English
FLUCONAZOLE [USP MONOGRAPH]
Common Name English
FLUCONAZOLE [ORANGE BOOK]
Common Name English
UK-49858
Code English
FLUCONAZOLE [WHO-IP]
Common Name English
NSC-758661
Code English
FLUCONAZOLE [WHO-DD]
Common Name English
ZOLTEC
Common Name English
FLUCONAZOLE [USP-RS]
Common Name English
FLUCONAZOLE [INN]
Common Name English
FLUCONAZOLE [EP MONOGRAPH]
Common Name English
FLUCONAZOLE [HSDB]
Common Name English
FLUCONAZOLE [MART.]
Common Name English
UK-49,858
Code English
DIFLUCONAZOLE
Common Name English
2,4-DIFLUORO-1',1'-BIS(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZYL ALCOHOL
Common Name English
ALKANAZOLE
Common Name English
FLUCONAZOLE [VANDF]
Common Name English
FLUCONAZOLE [JAN]
Common Name English
FLUCONAZOLE [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC J01RA07
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
WHO-VATC QD01AC15
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
WHO-ATC J02AC01
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
NDF-RT N0000008217
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
WHO-ATC D01AC15
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
NCI_THESAURUS C514
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
WHO-VATC QJ02AC01
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
LIVERTOX 418
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
NDF-RT N0000175487
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.3
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C500
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL106
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
MERCK INDEX
M5423
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY Merck Index
INN
5851
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
DRUG CENTRAL
1187
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
EVMPD
SUB07674MIG
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
HSDB
7420
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
DRUG BANK
DB00196
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
LACTMED
Fluconazole
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
WIKIPEDIA
FLUCONAZOLE
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
CAS
86386-73-4
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
RXCUI
4450
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY RxNorm
PUBCHEM
3365
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUCONAZOLE
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Slightly soluble in water, freely soluble in methanol, soluble in acetone.Category: Antifungal.Storage: Fluconazole should be kept in a tightly closed container.Additional information: Fluconazole is hygroscopic and exhibits polymorphism.Definition: Fluconazole contains not less than 99.0% and not more than 101.0% of C13H12F2N6O, calculated with reference to the dried substance.
USP_CATALOG
1271700
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY USP-RS
EPA CompTox
86386-73-4
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
FDA UNII
8VZV102JFY
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
MESH
D015725
Created by admin on Fri Jun 25 21:04:59 UTC 2021 , Edited by admin on Fri Jun 25 21:04:59 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> INHIBITOR
IC50
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
INHIBITOR -> METABOLIC ENZYME
METABOLIC ENZYME -> INHIBITOR
MAJOR
METABOLIC ENZYME -> INHIBITOR
IC50
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
IMPURITY -> PARENT
In the chromatogram obtained with solution (1): ? the area of any peak corresponding to impurity A is not is not greater than 0.8 times the area of the principal peak in the chromatogram obtained with solution (2) (0.4 %).
IMPURITY -> PARENT
Fluconazole Impurity H Amount Not Specified.
IMPURITY -> PARENT
Fluconazole Impurity I Amount Not Specified.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Fluconazole Impurity G Amount Not Specified.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Fluconazole Impurity E Amount Not Specified.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
In the chromatogram obtained with solution (1):? the area of any peak corresponding to impurity B, when multiplied by a correction factor of 1.5, is not greater than 0.3 times the area of the principal peak in the chromatogram obtained with solution (3) (0.3 %).
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Fluconazole Impurity F Amount Not Specified.
IMPURITY -> PARENT
Amount not specified.
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
The test is not valid, unless in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and fluconazole is at least 3.0. In the chromatogram obtained with solution (1):? the area of any peak corresponding to impurity C is not is not greater than 0.1 times the area of the principal peak in the chromatogram obtained with solution (3) (0.1 %).
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MAXIMUM TOLERATED DOSE TOXICITY
Route of Elimination PHARMACOKINETIC ELDERLY: 22% UNCHANGED

EXCRETED AS METABOLITE: 11%

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC CHILDREN, AGE 9 MONTHS TO 15 YEARS: 15.2 - 25 HOURS

ELDERLY: 46.2 HOURS

PREMATURE NEWBORNS, GESTATIONAL AGE 26 - 29 WEEKS: 73.6 HOURS (WITHIN 36 HOURS OF BIRTH), MEAN OF 53.2 HOURS (6 DAYS LATER) AND 46.6 HOURS (12 DAYS LATER)

Biological Half-life PHARMACOKINETIC
Cmax PHARMACOKINETIC Route

Dose
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

Tmax PHARMACOKINETIC EFFECT OF FOOD: NONE

Volume of Distribution PHARMACOKINETIC ROUTE OF AMINISTRATION: IV

ORAL BIOAVAILABILITY PHARMACOKINETIC EFFECT OF FOOD: NONE

PROTEIN BINDING PHARMACOKINETIC
Cmax PHARMACOKINETIC ROUTE
PHARMACOKINETIC
DOSE
PHARMACOKINETIC